Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)Research in context
Summary: Background: Assessment of germline (g) BRCA1/2 status is recommended for all patients with HER2-negative metastatic breast cancer (MBC) to identify candidates for poly(ADP-ribose) polymerase (PARP) inhibitor therapy, which is not always possible in clinical practice due to limited testing...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | The Lancet Regional Health. Western Pacific |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666606525001592 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Summary: Background: Assessment of germline (g) BRCA1/2 status is recommended for all patients with HER2-negative metastatic breast cancer (MBC) to identify candidates for poly(ADP-ribose) polymerase (PARP) inhibitor therapy, which is not always possible in clinical practice due to limited testing resources. In this study, we investigate the cross-sectional prevalence of gBRCA1/2 pathogenic variant (PV) carriers in unselected Korean patients with HER2-negative MBC. Methods: Patients diagnosed with HER2-negative metastatic BC receiving palliative systemic treatment were eligible for inclusion in the study. Peripheral blood was prospectively drawn from each patient and gBRCA1/2 status was assessed by next-generation sequencing using an NGeneBio BRCAaccuTest. Findings: A total of 586 patients were enrolled between October 2019 and March 2022, and the prevalence of gBRCA1/2 PV was analyzed in 570 patients. The median age at enrollment was 54 years (interquartile range, 48–61) and 567 patients were female. Among the 570 patients with gBRCA1/2 analysis, 481 had hormone receptor–positive/HER2-negative breast cancer (BC) and 89 had triple-negative breast cancer (TNBC). The overall prevalence of gBRCA1/2 PV carriers was 7.4% (42/570, 95% confidence interval (CI) 5.4%–9.8%) in unselected patients with HER2-negative MBC [gBRCA1, 1.8% (95% CI 0.8%–3.2%), 10/570; gBRCA2, 5.6%(95% CI % - 7.8%), 32/570]. The overall prevalence of gBRCA1/2 PV carriers in Korean patients with HER2-negative MBC and a low risk of hereditary breast ovarian cancer syndrome (HBOC) was 5.7% [19/332, 95% confidence interval 3.5%–8.8%; TNBC 10.5% (95% CI 1.3%–33.1%), 2/19; HR-positive/HER2-negative 5.4%(95% CI 3.2%–8.6%), 17/313]. Interpretation: Our study measured the size of the current underestimation of gBRCA1/2 PV carriers in unselected Korean patients with HER2-negative MBC, particularly in patients without high risk factors for HBOC. An active screening strategy for unselected HER2-negative MBC should be pursued to avoid missing potential candidates for systemic treatment with PARP inhibitors. Funding: Pfizer. |
|---|---|
| ISSN: | 2666-6065 |